Related references
Note: Only part of the references are listed.Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials
Ana Arias et al.
ANTIVIRAL THERAPY (2017)
Hep C, Where Art Thou: What Are the Remaining (Fundable) Questions in Hepatitis C Virus Research?
Hugo Ramon Rosen
HEPATOLOGY (2017)
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance Associated Polymorphisms
Ling Tong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
HIGH SVR RATES WITH EIGHT AND TWELVE WEEKS OF PANGENOTYPIC GLECAPREVIR/PIBRENTASVIR: INTEGRATED EFFICACY ANALYSIS OF GENOTYPE 1-6 PATIENTS WITHOUT CIRRHOSIS
Massimo Puoti et al.
GASTROENTEROLOGY (2017)
MAGELLAN-1, PART 2: GLECAPREVIR AND PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE
Fred Poordad et al.
GASTROENTEROLOGY (2017)
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson et al.
GASTROENTEROLOGY (2017)
Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment
Fred Poordad et al.
HEPATOLOGY (2017)
Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus
Eric Lawitz et al.
HEPATOLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries
Narcyz Ghinea et al.
LANCET (2017)
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
Velia C. Di Maio et al.
LIVER INTERNATIONAL (2017)
Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure
Cornelia Metzig et al.
SCIENTIFIC REPORTS (2017)
Sofosbuvir and velpatasvir for the treatment of hepatitis C
Whitney E. Jackson et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
Steven W. Johnson et al.
CURRENT INFECTIOUS DISEASE REPORTS (2017)
Hepatitis C virus infection
Michael P. Manns et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility
Suzanne Molino et al.
ANNALS OF PHARMACOTHERAPY (2017)
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I. Ng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
Eric J. Lawitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir
Erik Mogalian et al.
CLINICAL PHARMACOKINETICS (2016)
Is HIV still a special population for the treatment of hepatitis C?
Edward Cachay et al.
AIDS (2016)
Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV
Christine E. MacBrayne et al.
CLINICAL INFECTIOUS DISEASES (2016)
Hepatitis C virus resistance to the new direct-acting antivirals
Isabella Esposito et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Prevention and management of treatment failure to new oral hepatitis C drugs
Laura Benitez-Gutierrez et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
Edward Gane et al.
GASTROENTEROLOGY (2016)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz et al.
GASTROENTEROLOGY (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
Why I do not treat patients for mild disease
Christophe Hezode
LIVER INTERNATIONAL (2016)
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Tariq Ahmad et al.
HEPATOLOGY (2015)
Management of direct-acting antiviral agent failures
Maria Buti et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rate, delay and predictors of hepatitis C treatment in British Columbia
Alan Hoi Lun Yau et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
R. S. Koff
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
VIRAL HEPATITIS Treating hepatitis C in injection drug users
Vincent Soriano et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Share Paper
